These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 29674658)

  • 1. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
    Jodele S; Dandoy CE; Myers K; Wallace G; Lane A; Teusink-Cross A; Weiss B; Davies SM
    Bone Marrow Transplant; 2018 Oct; 53(10):1311-1318. PubMed ID: 29674658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
    Schoettler M; Lehmann L; Li A; Ma C; Duncan C
    Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.
    Tolbert VP; Dvorak CC; Golden C; Vissa M; El-Haj N; Perwad F; Matthay KK; Vo KT
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2031-2039. PubMed ID: 31199983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
    Elborai Y; Hafez H; Moussa EA; Hammad M; Hussein H; Lehmann L; Elhaddad A
    Pediatr Transplant; 2016 Mar; 20(2):284-9. PubMed ID: 26614402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
    Desai AV; Heneghan MB; Li Y; Bunin NJ; Grupp SA; Bagatell R; Seif AE
    Bone Marrow Transplant; 2016 Sep; 51(9):1204-10. PubMed ID: 27159174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide and Thiotepa Increases Risk of Transplant-Associated Thrombotic Microangiopathy.
    Higham CS; Shimano KA; Kharbanda S; Chu J; Cisneros GS; Winestone LE; Dara J; Huang JN; Hermiston ML; Long-Boyle JR; Dvorak CC
    Transplant Cell Ther; 2024 Sep; 30(9):931.e1-931.e10. PubMed ID: 38944154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
    Desai AV; Li Y; Getz K; Seif AE; Fisher B; Huang V; Aplenc R; Bagatell R
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27372. PubMed ID: 30070014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
    Desai AV; Seif AE; Li Y; Getz K; Fisher BT; Huang V; Mante A; Aplenc R; Bagatell R
    Pediatr Blood Cancer; 2016 May; 63(5):901-7. PubMed ID: 26797923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
    Kato S; Kubota Y; Watanabe K; Hogetsu K; Arakawa Y; Koh K; Takita J; Hiwatari M
    Pediatr Transplant; 2020 Nov; 24(7):e13772. PubMed ID: 32543778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab.
    Schoettler M; Duncan C; Lehmann L
    Pediatr Transplant; 2019 May; 23(3):e13381. PubMed ID: 30828947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
    Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
    Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
    Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
    Transplant Cell Ther; 2024 Jun; 30(6):601.e1-601.e13. PubMed ID: 38521410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
    Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractionated total body irradiation, high-dose melphalan, etoposide, and carboplatin (FTBI-MEC) for autologous stem cell transplantation in children with advanced neuroblastoma and primitive neuroectodermal tumor.
    Emminger W; Gadner H
    Pediatr Hematol Oncol; 1992; 9(2):183-5. PubMed ID: 1356004
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
    Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
    Front Immunol; 2020; 11():564647. PubMed ID: 33552043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.
    Eltelbanei MA; El-Bassiouny NA; Abdalla MS; Khalaf M; Werida RH
    BMC Cancer; 2024 Aug; 24(1):1002. PubMed ID: 39134959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
    Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
    Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab.
    Nozawa A; Ozeki M; Hori T; Kawamoto N; Hirayama M; Azuma E; Fukao T
    J Pediatr Hematol Oncol; 2018 Nov; 40(8):e544-e546. PubMed ID: 28991129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients.
    Rudoni J; Jan A; Hosing C; Aung F; Yeh J
    Eur J Haematol; 2018 Sep; 101(3):389-398. PubMed ID: 29920784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Application of Recently Proposed ASTCT/CIBMTR/EBMT/APBMT Consensus Risk Stratification for Transplantation-Associated Thrombotic Microangiopathy in Children.
    Schoettler ML; Ofori J; Bryson E; Spencer K; Qayed M; Stenger E; Bidgoli A; Chonat S; Westbrook A; Williams KM
    Transplant Cell Ther; 2024 Sep; 30(9):929.e1-929.e6. PubMed ID: 38936547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.